Allison Florance

Medicine · Health Sciences

16h-index2.8kcitations39works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(22), HER2/EGFR in Cancer Research(21), Advanced Breast Cancer Therapies(21), HIV/AIDS drug development and treatment(4), Health Systems, Economic Evaluations, Quality of Life(4)

Publications39 total

Supplementary Table 1 from Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2023Open Access
Supplementary Table 1 from Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2023Open Access
Data from Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2023Open Access
CCR Translation for This Article from Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2023Open Access
Data from Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2023Open Access
CCR Translation for This Article from Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2023Open Access
Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory <i>BRAF</i> V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).
Journal of Clinical Oncology·2015· 33 cited
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling
BMC Research Notes·2013· 74 citedOpen Access
Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Clinical Cancer Research·2013· 26 citedOpen Access
An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
The Oncologist·2013· 19 citedOpen Access
My climb up the corporate ladder: lessons learned
AMSTAT news: the membership magazine of the American Statistical Association·2013
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
Journal of Clinical Oncology·2012· 541 cited
VEGF polymorphism may be associated with overall survival in lapatinib-treated breast cancer patients with brain metastases.
Journal of Clinical Oncology·2012
ALTERNATIVE (EGF114299): A study of lapatinib, trastuzumab, and endocrine therapy in patients who received neo-/adjuvant trastuzumab (IV) and endocrine therapy.
Journal of Clinical Oncology·2012
S1-4: Retrospective Analysis of Study EGF30008 by Mass-Spectrometry Based Serum Assay (VeriStrat®).
Cancer Research·2011· 3 cited
OT1-02-03: EGF114299: Safety and Efficacy of an Aromatase Inhibitor (AI) in Combination with Lapatinib (L), Trastuzumab (T) or Both for the Treatment of Hormone Receptor-Positive (HR+), HER2+ Metastatic Breast Cancer (MBC).
Cancer Research·2011· 1 cited
Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.
Journal of Clinical Oncology·2011· 48 cited
Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+ metastatic breast cancer.
Journal of Clinical Oncology·2010· 6 cited
Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer
The Oncologist·2010· 13 citedOpen Access
Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer
The Oncologist·2010· 189 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Lisa O’Rourke(17), Stephen Johnston(14), Michael F. Press(10), J. Maltzman(9), Catherine Ellis(9), Judy Dering(8), John Pippen(7), Xavier Pivot(7), Richard S. Finn(7), Anne‐Marie Martin(7), Henry Gómez(5), Sandra Franco(5), S. Johnston(5), María Koehler(4), Alexey Manikhas(3), Steven Stein(3), Mark D. Pegram(3), Francisco J. Esteva(3), Mikhail Lichinitser(2), Saeed Sadeghi(2)